Abstract:Background Emerging studies revealed that cancer stem cells (CSCs) possessed peculiar metabolic properties, which however remained largely unknown in hepatocellular carcinoma (HCC). Genetic silencing of liver-abundant miR-192-5p was a key feature for multiple groups of CSC-positive HCCs. We thus aimed to investigate essential metabolic features of hepatic CSCs via using HCCs with miR-192-5p silencing as a model. Methods Datasets from two independent HCC cohorts were used. Data integration analyses of miR-192-5p with metabolome and mRNA transcriptome data in HCC Cohort 1 were performed to investigate miR-192-5p related metabolic features, which was further validated in Cohort 2. Cellular and molecular assays were performed to examine whether and how miR-192-5p regulated the identified metabolic features. Co-culture systems consisting of HCC cells and LX2 (human hepatic stellate cell line) or THP1 (human monocyte cell line) were established to explore effects of the identified metabolic properties on stemness features of HCC cells via interacting with co-cultured non-tumor cells. Results High levels of glycolysis-related metabolites and genes were present in HCCs with low miR-192-5p and CSC-positive HCCs in two independent HCC cohorts. miR-192-5p knockout cells displayed CSC features and miR-192-5p loss led to an enhanced glycolytic phenotype via upregulating three bona fide targets, GLUT1 and PFKFB3 (two glycolytic enzymes) and c-Myc (regulating glycolytic genes’ expression). Meanwhile, c-Myc suppressed miR-192-5p transcription, ensuring a low-miR-192-5p/high-c-Myc loop to maintain hyperglycolysis. Moreover, over-produced lactic acid from hyperglycolytic HCC cells stimulated the ERK phosphorylation of co-cultured LX2 and THP1 non-tumor cells partially via NDRG3 and MCT1, which in turn promoted cell malignancy and stemness of HCC cells. Consistently, HCC patients with low level of miR-192-5p in their tumor tissues and high level of NDRG3 or MCT1 in their non-tumor tissues had the shortest overall survival. Conclusions In CSC-positive HCCs, miR-192-5p loss enhanced glycolysis and over produced lactate might further increase HCC malignant features via interacting with environmental non-tumor cells.

LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

Long Non-Coding RNA LINC01572 Promotes Hepatocellular Carcinoma Progression via Sponging miR-195-5p to Enhance PFKFB4-Mediated Glycolysis and PI3K/AKT Activation

Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

Long noncoding LINC00238 restrains Hepatocellular Carcinoma Malignant Phenotype via Sponging miR-522

Down-regulation of Long Non-coding RNA LINC01554 in Hepatocellular Cancer and Its Clinical Significance.

LINC00365 functions as a tumor suppressor by inhibiting HIF-1?-mediated glucose metabolism reprogramming in breast cancer

LINC00365 functions as a tumor suppressor by inhibiting HIF-1α-mediated glucose metabolism reprogramming in breast cancer.

LINC00659 Inhibits Hepatocellular Carcinoma Malignant Progression by Blocking Aerobic Glycolysis Through FUS Recruitment and SLC10A1 Modulation

Glucose‐induced LINC01419 reprograms the glycolytic pathway by recruiting YBX1 to enhance PDK1 mRNA stability in hepatocellular carcinoma

LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/ SOSC2 axis

M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma

Epigenetic Silencing of LncRNA LINC00261 Promotes C-Myc-mediated Aerobic Glycolysis by Regulating Mir-222-3p/hipk2/erk Axis and Sequestering IGF2BP1

A feedback loop between NONHSAT024276 and PTBP1 inhibits tumor progression and glycolysis in HCC by increasing the PKM1/PKM2 ratio

Long Noncoding RNA CERS6-AS1 Modulates Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma by Promoting the MDM2/p53 Signaling Pathway

LINC01018 Confers a Novel Tumor Suppressor Role in Hepatocellular Carcinoma Through Sponging Microrna-182-5p

LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles

Long Noncoding RNA SLC2A1‐AS1 Regulates Aerobic Glycolysis and Progression in Hepatocellular Carcinoma Via Inhibiting the STAT3/FOXM1/GLUT1 Pathway

LINC00152 Promotes Cell Cycle Progression in Hepatocellular Carcinoma Via Mir-193A/b-3p/ccnd1 Axis

Long non-coding RNA<i> 01559</i> mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting<i> miR-511</i>